Cimetropium bromide, a new antispasmodic compound: pharmacology and therapeutic perspectives.
The pharmacology and clinical use of cimetropium bromide is reviewed. Experimental and clinical data demonstrated that this new compound is a potent antimuscarinic and an effective antispasmodic drug. It is also endowed of a direct myolitic action which partially accounts for its antispasmodic activity. Clinical trials as yet performed confirmed its efficacy in many painful conditions of the gastrointestinal, biliary and genitourinary tracts, as well as its usefulness as a pre-endoscopic medication. Finally, the drug proved to be well tolerated, with a low incidence of atropine-like untoward effects.
D000818:Animals; D000897:Anti-Ulcer Agents; D001285:Atropine / Q000494:pharmacology; D005753:Gastric Mucosa / Q000187:drug effects / Q000378:metabolism; D005769:Gastrointestinal Motility / Q000187:drug effects; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D007700:Kinetics; D009119:Muscle Contraction / Q000187:drug effects; D010276:Parasympatholytics / Q000138:chemical synthesis / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use / Q000633:toxicity; D011680:Pupil / Q000187:drug effects; D012472:Salivation / Q000187:drug effects; D012602:Scopolamine Derivatives / Q000138:chemical synthesis / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use / Q000633:toxicity
D000897:Anti-Ulcer Agents; D010276:Parasympatholytics; D012602:Scopolamine Derivatives; C016859:cimetropium; D001285:Atropine